PFIZER: PATTEGGIA 2,3 MILIARDI IN USA PER MARKETING SCORRETTO

PFIZER: PATTEGGIA 2,3 MILIARDI IN USA PER MARKETING SCORRETTO
(AGI/REUTERS) – Washington, 2 set. – Il colosso farmaceutico Pfizer si e’ dichiarato colpevole di pratiche commerciali scorrette sul mercato statunitense e ha accettato di pagare una multa da 2,3 miliardi di dollari. A rendere noto il patteggiamento, il piu’ elevato di sempre per tali capi di imputazione, e’ il dipartimento di Giustizia di Washington. La societa’ e’ stata ritenuta piu’ volte colpevole di aver fatto ricorso a pratiche commerciali illegali per promuovere tredici farmaci, tra i quali l’antidolorifico Bextra, ritirato dal mercato nel 2005, lo psicofarmaco Geodon, l’antibiotico Zyvox e Lyrica, utilizzato per trattare malattie nervose e convulsioni. Alcuni illeciti riguardano la vendita di farmaci “off-label”, ovvero per usi non autorizzati dalla Food and Drug Administration, e versamenti illegali a professionisti del settore sanitario. (AGI) The settlement announced on Wednesday by Pfizer includes a $1.3 billion criminal fine related to methods of selling Bextra, which was withdrawn from the market in 2005 on safety concerns. It also includes $1 billion in civil payments related to so-called “off-label” sales of drugs — meaning for uses not authorized by the U.S. Food and Drug Administration — and payments to healthcare professionals. “We regret certain actions taken in the past, but are proud of the action we’ve taken to strengthen our internal controls,” said Amy Schulman, Pfizer’s general counsel. The company said most of the alleged improprieties took place during or before 2005. Company Chief Executive Jeffrey Kindler had been Pfizer’s general counsel from 2002 until taking the helm in 2006. Pfizer had pleaded guilty in 2004 to an unrelated criminal charge of improper sales tactics related to its Neurontin seizure drug and its marketing practices have been under federal supervision since then. In the earlier case, Pfizer’s Warner Lambert subsidiary had been accused of marketing Neurontin for unapproved uses. Pfizer acquired Neurontin through its merger in 2000 with Warner Lambert. Pfizer agreed in 2004 to pay $430 million to federal and state governments and pleaded guilty to criminal charges of illegally marketing Neurontin for migraine headaches, pain and bipolar disorder. Pfizer shares were little changed at $16.36 in morning trading on the New York Stock Exchange.

Share on FacebookTweet about this on TwitterPin on PinterestShare on LinkedIn

Articoli correlati

Il presidente iraniano Rohani: statue coperte? E’ solo un caso giornalistico

Il presidente iraniano Rohani: statue coperte? E’ solo un caso giornalistico

Padre Ciro Benedettini lascia la vicedirezione della sala stampa vaticana dopo 22 anni di servizio

Padre Ciro Benedettini lascia la vicedirezione della sala stampa vaticana dopo 22 anni di servizio

Convocata per le 14:30 di oggi un’assemblea del Cdr di Rainews con Usigrai e Fnsi

Convocata per le 14:30 di oggi un’assemblea del Cdr di Rainews con Usigrai e Fnsi